Keith A. Meister

Keith A. Meister, listed as senior executive, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Illumina, Inc., GeneDx Holdings Corp. and Vestis Corp. Between 14 February 2022 and 30 September 2026, the trades on record add up to 112 filings.

In open-market terms, that means 15 purchases worth €75.3M on one side and 77 sales worth €423.1M on the other. On balance, insiders were net sellers of €347.8M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 15 share grants and 4 option exercises. In 2026 alone, the filings show 7 purchases and 68 sales.

In size, the median ticket on the buying side is €2.0M. Relative to company size, the median is 0.11% of market cap (6 purchases with a known value). 6 out of 15 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 14 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 64% of cases, with a median move of +80.5%. Past outcomes like these are no guarantee of what comes next.

Most recently, on 2 October 2026, the filings show a share grant worth €21k in Illumina, Inc. The latest purchase dates back some time: it was published 155 days ago, on 15 May 2026. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.